Olmetec elderly dose restriction lifted

The licence for Olmetec (olmesartan medoxomil) has been extended.

The licence now includes the use of 40mg daily in the elderly. Previously elderly patients were restricted to a maximum dose of 20mg due to a lack of available clinical data in this patient population.

If up-titration to the maximum dose of 40mg is required, blood pressure should be closely monitored.
Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

Live updates: Coronavirus (COVID-19) in the UK

Live updates: Coronavirus (COVID-19) in the UK

Use our timeline to follow the latest coronavirus developments...

Free resources on MIMS Learning keep you updated on COVID-19

Free resources on MIMS Learning keep you updated on COVID-19

MIMS Learning has a range of free resources for healthcare...

First oral GLP-1 agonist launched for type II diabetes

First oral GLP-1 agonist launched for type II diabetes

Prescribers can now consider a GLP-1 agonist as an...

Drug shortages - live tracker

Drug shortages - live tracker

Use our constantly updated shortages tracker to check...